Imperial College London
Alternate

Dr Antonio J Berlanga-Taylor

Faculty of Medicine, School of Public Health

Honorary Senior Research Fellow
 
 
 
//

Contact

 

a.berlanga

 
 
//

Location

 

47 Praed StreetSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Berlanga-Taylor:2013:10.1517/17530059.2013.786040,
author = {Berlanga-Taylor, AJ and Ramagopalan, SV},
doi = {10.1517/17530059.2013.786040},
journal = {Expert Opin Med Diagn},
pages = {227--229},
title = {Vitamin D and multiple sclerosis: what is the clinical impact?},
url = {http://dx.doi.org/10.1517/17530059.2013.786040},
volume = {7},
year = {2013}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Evidence for a causal role for vitamin D in multiple sclerosis (MS) is being gathered. Epidemiological, molecular and animal model studies have paved the way in our understanding of the effects of vitamin D in demyelinating disease. Several clinical trials have been completed and more are under way to understand the full extent and value of vitamin D supplementation on disease progression. Many questions remain unanswered however and careful study design is increasingly pertinent. Timing of exposure, dosage and transgenerational effects are some of the several important questions that need to be addressed. In this issue, Carlson and Rose highlight these points and provide a review of vitamin D and MS with an emphasis on the most recent clinical studies. Further evidence of vitamin D deficiency as a causal factor, its molecular targets in MS and its prospect as a therapeutic and preventative agent are questions that warrant further study.
AU  - Berlanga-Taylor,AJ
AU  - Ramagopalan,SV
DO  - 10.1517/17530059.2013.786040
EP  - 229
PY  - 2013///
SP  - 227
TI  - Vitamin D and multiple sclerosis: what is the clinical impact?
T2  - Expert Opin Med Diagn
UR  - http://dx.doi.org/10.1517/17530059.2013.786040
UR  - https://www.ncbi.nlm.nih.gov/pubmed/23565817
VL  - 7
ER  -
Download